Article

Coronary heart disease in women with diabetes. Positive association with past hysterectomy and possible benefits of hormone replacement therapy.

Diabetes Care (Impact Factor: 8.57). 06/1999; 22(5):856-7. DOI: 10.2337/diacare.22.5.856
Source: PubMed
Download full-text

Full-text

Available from: Geraldine M Leydon, Jun 17, 2015
0 Followers
 · 
51 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen derives its name from the Greek word “oistros” that means to “drive mad with desire.” More than a century ago, it was thought that peripheral vascular function could be influenced by the “evil effects” emanating from the female apparatus (1). Thus, early beliefs regarding the effects of estrogens were shrouded in curiosity and fear. Even today, although estrogens are no longer considered to have an “evil” influence, their biological effects remain somewhat mysterious and controversial.
    12/2004: pages 129-165;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-dose hormone replacement therapy (HRT) has attracted interest for the treatment of postmenopausal symptoms in diabetes because of concerns about increased risk of coronary heart disease (CHD) and stroke with conventional HRT containing conjugated equine oestrogens (CEEs) and medroxyprogesterone acetate (MPA). We assessed the effects on glucose homeostasis and cardiovascular risk factors of continuous oral 17beta oestradiol (1 mg) and norethisterone (0.5 mg) in postmenopausal women with type 2 diabetes. Double-blind, randomized placebo-controlled trial. Hyperinsulinaemic isoglycaemic clamp and cardiovascular risk factors were assessed before and after 3 months of treatment. Twenty-eight women completed the study. HRT decreased fasting glucose compared with placebo [-9.4% with HRT vs.+2.3% for placebo, 95% confidence interval (CI) -23.2 to -0.3] and total cholesterol (-13.7 vs.+1.0%, 95% CI -22.4 to -3.1%) No significant effect was seen on metabolic clearance rate of glucose, glycated haemoglobin (HbA1c), triglycerides, high density lipoprotein (HDL)-cholesterol or C-reactive protein (CRP). In women with type 2 diabetes, low-dose HRT decreased fasting glucose and total cholesterol without detectable adverse effects on glucose clearance, triglycerides and CRP as reported with conventional HRT.
    Clinical Endocrinology 02/2007; 66(1):27-34. DOI:10.1111/j.1365-2265.2006.02679.x · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: (1) Describe women's (a) hormone replacement therapy (HRT) use patterns, (b) intentions to use or continue to use HRT among women in the early and late stages of menopause, and (c) beliefs about using HRT and (2) compare these beliefs, patterns, and intentions between women with and without diabetes 10-12 months after news from the women's health initiative was widely publicized. A survey mailed to female enrollees of a not-for-profit managed care organization (MCO) between 46 and 60 years of age and with or without diabetes. Descriptive statistics were calculated. Chi-square analysis was used to determine significant differences between four different HRT use and menopause stage groups, (1) early stage never user, (2) late stage never user, (3) late stage current user, and (4) late stage previous user. Analysis of variance (ANOVA) was used to identify significant belief differences between the four groups. Repeated-measures ANOVA was performed to examine differences between women with and without diabetes. Most women did not intend to initiate HRT. About 86% of current HRT users intended to continue. Never users with diabetes were significantly more uncertain about HRT intention than non-diabetic women. All beliefs were significantly different (p<0.001) between the four groups, but not between women with and without diabetes. Women in different groups hold different beliefs about HRT use. Uncertainty among women with diabetes is not resolved as quickly as among women without diabetes.
    Maturitas 09/2006; 55(1):58-68. DOI:10.1016/j.maturitas.2006.01.004 · 2.86 Impact Factor